Patent: 10,016,365

Summary for Patent: 10,016,365

Title:	Compositions and methods of tumor treatment utilizing nanoparticles
Abstract:	The present invention is directed to a method for treating cancer intraperitoneally in a subject. The method comprises administering to said subject in need thereof an anti-cancer agent encapsulated in nanoparticles wherein nanoparticles are characterized to slowly release anti-cancer agent in a timely fashion that allows efficient killing of tumor cells. The nanoparticles described herein are characterized to slowly release anti-cancer agent at a rate of 30% or less per 24 hours based on in vitro drug dissolution study.
Inventor(s):	Chuang; Chi-Mu (Taipei, TW), Chang; Chi-Tai (Taipei, TW)
Assignee:	OP NANO CO., LTD. (Taipei, TW) TRENDMED CO., LTD. (Beitou Dist., Taipei, TW)
Application Number:	15/550,786
Patent Claims:	see list of patent claims

US Patent 10,016,365: What Do the Claims Actually Cover—and Where Is the Patent Vulnerable?

What is the core claim set across US 10,016,365?

US 10,016,365 is framed as regional intraperitoneal or intrapleural delivery of anti-cancer agents encapsulated in liposomes built from a specific lipid composition and constrained by a release-rate ceiling tied to an in vitro dissolution metric.

Independent method claim (Claim 1)

• Route: intraperitoneal (IP)
• Carrier: liposomes
• Lipids required (all):
  • hydrogenated soy phosphatidylcholine (HSPC)
  • cholesterol
  • d-alpha-tocopheryl polyethylene glycol succinate (TPGS)
• Release constraint: “slowly release” drug at ≤ 30% per 24 hours based on in vitro drug dissolution
• Use context: “method for treating cancer in a subject”

Dependent scope expansions

• Claim 2: very broad list of possible anti-cancer agents and combinations (covers many small molecules and biologics, including paclitaxel and targeted kinase inhibitors).
• Claim 3: paclitaxel specifically
• Claim 4-5: cancer type restriction (ovarian or colon among others)
• Independent regional-delivery substitute (Claim 6):
  • Route: intrapleural
  • Carrier: liposomes with the same required lipid set
  • Release constraint: same ≤ 30% per 24 hours (in vitro dissolution)
• Claim 7-10: cancer-type options, metastasis, “severe adhesion in the peritoneal cavity” and paclitaxel again.

What is the enforceable technical “center of gravity”?

From a validity and infringement standpoint, this patent’s enforceable hooks concentrate in three technical elements:

1. Specific liposomal composition identity (not just “liposomes”)

   • Requires HSPC + cholesterol + TPGS, and does not permit omission of any component in the claim language.

2. Regional delivery as a method-of-use

   • IP for Claim 1 and intrapleural for Claim 6.

3. Release-rate limitation tied to an in vitro dissolution metric

   • “≤ 30% per 24 hours” based on in vitro drug dissolution.
   • This becomes a key discriminator in both claim construction and non-infringement arguments.

How do these claims map to known liposome and TPGS formulation IP?

Are HSPC/cholesterol/TPGS liposomes already established?

TPGS is a widely used formulation excipient in drug delivery for permeability modulation and formulation stabilization. HSPC/cholesterol are standard lipid scaffolds for robust, low-leak liposomes. The combination is likely within the orbit of earlier liposomal and TPGS-based drug delivery disclosures.

From an investor or R&D diligence angle, the practical issue is not whether any one element is novel in isolation, but whether US 10,016,365’s claim pack:

• is novel as a combination,
• is non-obvious over prior art systems,
• and is written tightly enough to prevent broad prior-art overlap.

The risk is that courts and examiners can treat:

• lipid selection as routine optimization,
• regional delivery as a known administration strategy,
• and slow release as an expected performance target that can be engineered.

What does the claim try to do to avoid obviousness?

The release-rate limitation and regional route do real work in the claim. But the phrasing creates vulnerabilities if prior art can show that:

• similar liposomes were made with HSPC + cholesterol + TPGS, and
• they had drug release curves consistent with the claimed ≤30%/24h ceiling,
• and they were tested using dissolution methods sufficiently similar to the claimed “in vitro drug dissolution.”

If earlier art includes any of the following, it can undercut novelty or obviousness:

• HSPC/cholesterol/TPGS liposomes containing oncology drugs,
• those liposomes used IP or pleural delivery,
• with quantified release behavior measured in vitro.

Where the patent is likely strongest: claim construction pressure points

1) The “all of” lipid requirement is a hard constraint

The claim requires liposomes “comprise all of”:

• HSPC
• cholesterol
• TPGS

That wording is helpful in infringement defense:

• A product using DSPC instead of HSPC, or replacing TPGS with another PEG-lipid (or using a non-TPGS PEG-lipid), creates a path to non-infringement if the substituted product cannot be argued to still “comprise all of” the required excipients.

Practical compliance implication

• If a competitor formulates around by changing any required lipid identity, US 10,016,365’s method claim becomes materially harder to assert.

2) The in vitro dissolution ceiling provides a quantitative discriminator

“Slowly release anti-cancer agent at a rate of 30% or less per 24 hours based on in vitro drug dissolution” introduces a measurable threshold. That creates room for:

• non-infringement by release kinetics, or
• at least a high evidentiary burden to prove infringement.

Why this matters

• In vitro release tests can vary based on membrane type, sink conditions, agitation, temperature, buffer composition, and quantification method.
• If an accused product’s release profile exceeds the ceiling under comparable testing, the patent’s reach narrows.

3) The route is baked in

IP delivery (Claim 1) and intrapleural delivery (Claim 6) are specified as method steps. Competitors who use other regional routes (e.g., direct tumor injection, IV administration, intracavitary but not pleural) can have a stronger non-infringement argument if route differs in claim interpretation.

Where the patent is likely weakest: breadth and mapping risk

Overbreadth: Claim 2 covers a wide drug universe with no formulation-specific tether

Claim 2 lists a large set of anti-cancer agents, including both:

• classic chemo agents and kinase inhibitors
• and biologics/antibodies (e.g., cetuximab, bevacizumab, ipilimumab, trastuzumab)
• and combinations

The problem for validity and enforceability is that the claim ties all these diverse payloads to one liposomal platform plus one release-rate ceiling, without requiring payload-specific formulation constraints (e.g., encapsulation efficiency, loading method, drug chemical form, stability issues).

This can create:

• enablement and written description stress in examination/litigation if the patent specification does not provide robust support for that entire payload list,
• and obviousness stress because prior art can supply multiple oncology drugs that can be loaded into liposomes as routine practice.

Payload-method disconnect

The claim treats payload substitution as a simple variable within the same liposomal architecture. If prior art demonstrates that multiple listed drugs were previously loaded into liposomes with slow release behavior, the “one formulation, many drugs” structure can become easy to attack.

The release metric may not be uniquely differentiating

If prior art already teaches that liposomal systems can be tuned to reach low-percentage release within 24 hours, the threshold may be characterized as an optimization rather than a patentable feature.

The release threshold becomes most powerful only if earlier art release curves demonstrably fail the ≤30%/24h limit under comparable in vitro conditions.

Patent landscape risk: what matters for competitors

Because the claims require a very particular lipid composition and a very specific release ceiling, the most relevant landscape items for freedom-to-operate (FTO) are not generic “liposome delivery” patents. They are patents and publications that show:

• HSPC + cholesterol + TPGS liposomes
• carrying at least one of the claimed oncology agents
• with quantified release over 24 hours at or below the claimed ceiling
• and using regional delivery compatible with IP or intrapleural delivery.

Most likely categories of adjacent prior art

1. TPGS-based liposome formulations for oncology

   • Look for disclosures with quantified release kinetics and lipid composition overlap.

2. HSPC/cholesterol liposome “slow release” technologies

   • Even if TPGS is absent in older art, some documents may argue that TPGS addition is routine.

3. Regional delivery of liposomal drugs

   • IP injection and pleural cavity delivery are common regional strategies, which can reduce novelty if combined with known liposome formulations.

4. Paclitaxel specific prior art

   • Claim 3 and Claim 10 add paclitaxel specificity. If paclitaxel-in-liposome prior art already discloses similar kinetics and lipid composition, that is a direct challenge.

Critical evaluation of individual claim elements for infringement/invalidity leverage

Claim 1 (IP + liposome + HSPC/cholesterol/TPGS + ≤30%/24h release)

Validity pressure points

• Novelty likely depends on whether any earlier disclosure already combined:
  • HSPC + cholesterol + TPGS liposomes
  • with intraperitoneal cancer therapy
  • and with ≤30% per 24 hours in vitro dissolution.

Infringement pressure points

• An accused product must match:
  • IP method step
  • liposomal composition including all three lipids
  • in vitro release profile at or under 30%/24h under relevant test conditions.

Claim 2 (drug list)

Validity pressure points

• Broadness increases obviousness and support risk.
• If a prior art reference teaches using the same liposomal platform for multiple chemo drugs, Claim 2’s breadth can be attacked as routine substitution.

Infringement pressure points

• If the accused payload drug is not in the Claim 2 list, Claim 1 may still apply depending on how “anti-cancer agent” is construed; but Claim 2 itself is a dependent narrowing.

Claim 3 / Claim 10 (paclitaxel)

These are not separate independent innovations; they narrow to a common oncology payload. Their leverage depends on whether:

• paclitaxel loading and release in similar liposomes were known with matching lipid composition and kinetics.

Claim 4-5 / Claim 7-8 (cancer types and metastasis)

Regional therapy claims can be narrowed to specific indications, but:

• if regional intraperitoneal or intrapleural delivery was known for cancer generally, cancer-type language may not add strong novelty unless coupled to specific device or formulation constraints.
• metastasis language (Claim 8) can be argued as a patient selection rather than a distinct technical feature.

Claim 9 (severe adhesion in peritoneal cavity)

This is a patient condition qualifier. For method claims, it can be attacked as:

• not changing the drug delivery system,
• and not limiting the technical method steps beyond patient selection.

What does this mean for investment R&D decisions?

For product teams designing next-generation regional liposomal oncology systems, US 10,016,365 imposes the clearest constraints on:

• composition identity: HSPC + cholesterol + TPGS must all be present
• kinetics target: ≤30% released per 24 hours by in vitro dissolution
• route of administration: intraperitoneal or intrapleural
• claimed drug scope: Claim 2 is broad, so FTO must cover multiple candidate payloads, not just one

Conversely, teams seeking a design-around have the most direct levers:

• swap lipid identity away from HSPC and/or away from TPGS,
• alter the in vitro release profile beyond the ≤30%/24h boundary (subject to feasibility and efficacy),
• shift away from IP or intrapleural route.

Key Takeaways

• US 10,016,365 centers on liposome regional delivery with a specified lipid triad (HSPC + cholesterol + TPGS) and a quantified release-rate ceiling (≤30% per 24h by in vitro dissolution).
• The claims are broad on payloads (Claim 2) and broad on cancer indications (Claims 4, 7), which increases the risk that novelty and non-obviousness arguments face prior-art combination challenges.
• The most enforceable constraints are the “all of” lipid requirement, the in vitro dissolution release threshold, and the route (IP vs intrapleural).
• The most practical infringement defenses/design-arounds are to change lipid identity (remove HSPC and/or TPGS), move release beyond the threshold, or change route.

FAQs

1. What is the single most important quantitative limitation in US 10,016,365?
   The liposomes must release the anti-cancer agent at ≤ 30% per 24 hours based on in vitro drug dissolution (Claims 1 and 6).

2. Does the patent require all three lipids in the liposome?
   Yes. The claims require the liposomes “comprise all of” HSPC, cholesterol, and TPGS (Claims 1 and 6).

3. Is paclitaxel only one option or a central option?
   Paclitaxel is explicitly called out in Claim 3 and Claim 10, but Claim 2 already covers a wide set of anti-cancer agents, including paclitaxel.

4. Do cancer-type qualifiers materially change the technical method?
   They narrow the clinical indication (Claims 4, 5, 7, 8) but do not change the required liposome composition, regional route, or release threshold in the claim language.

5. What is the main way competitors can design around?
   Change the formulation so it does not meet the required lipid triad (remove/replace HSPC and/or TPGS), or adjust the in vitro release profile so it exceeds the ≤30%/24h requirement, or use a different route than IP or intrapleural.

Citations
No sources were provided in the prompt for US 10,016,365 or for the specification, prosecution history, or bibliographic details needed to support an evidence-based patent landscape and claim validity analysis with inline citations. Therefore, no citations are included.

Details for Patent 10,016,365

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	September 25, 1998		2036-02-12
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	February 10, 2017		2036-02-12
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	February 12, 2004		2036-02-12